Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.190 -0.030 (-2.46%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

2 Exciting Biotech Stocks to Buy With Less Than $10 ↗

October 11, 2023

You can pick up these stocks for a song right now.

Via The Motley Fool

Big Pharma Could Transform Into BioTech Pharma ↗

October 10, 2023

As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall...

Via Benzinga

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip ↗

October 10, 2023

Wall Street price targets suggest this stock can rocket more than 400% higher.

Via The Motley Fool

2 Magnificent Growth Stocks to Buy On the Dip ↗

September 27, 2023

It might be time to catch these falling knives.

Via The Motley Fool

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

September 27, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

Where Caribou Biosciences Stands With Analysts ↗

July 26, 2023

Via Benzinga

2 Stocks I'm Buying on the Dip This Week ↗

July 17, 2023

Caribou Biosciences and AT&T screen as incredible bargains for patient investors.

Via The Motley Fool

1 Gene Editing Stock to Buy Now, and 1 to Sell ↗

September 23, 2023

Target markets matter. So does having the cash to get to them.

Via The Motley Fool

Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday ↗

September 18, 2023

U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Caribou Biosciences to Participate in Upcoming Investor Conferences

August 29, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

3 Clever Tricks to Find Winning Biotech Stocks ↗

August 24, 2023

You'll need to dig into company details, but the effort is worthwhile.

Via The Motley Fool

2 Magnificient Growth Stocks to Buy in July ↗

July 13, 2023

These two growth stocks might be incredibly undervalued right now.

Via The Motley Fool

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

August 08, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond ↗

July 28, 2023

Early-stage biotechs almost never warrant this level of enthusiasm.

Via The Motley Fool

NXP Semiconductors To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

July 26, 2023

HC Wainwright & Co. cut the price target for Caribou Biosciences, Inc. (NASDAQ: CRBU) from $25 to $23. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating. Caribou Biosciences shares fell...

Via Benzinga

This 1 Innovation Could Make These 2 Biotechs Soar by 2030 ↗

July 22, 2023

Simplifying the cell therapy manufacturing process could be worth a lot of money.

Via The Motley Fool

Got $1,000? Buying Caribou Biosciences Stock Right Now Could Be a Brilliant Move in 5 Years ↗

July 21, 2023

It's still early going, but this small biotech shows great promise.

Via The Motley Fool

2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street ↗

July 20, 2023

The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future.

Via The Motley Fool

MarketBeat Week in Review – 7/10 - 7/14

July 15, 2023

As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week

Via MarketBeat

Topics Economy

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 14, 2023

Via Benzinga

Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 14, 2023

Gainers PainReform Ltd. (NASDAQ: PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million concurrent registered direct offering and private placement.

Via Benzinga

Caribou Biosciences Raises $125M Via Equity Just One Week After Pfizer Invested $25M ↗

July 14, 2023

Caribou Biosciences Inc (NASDAQ: CRBU) reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 14, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 14, 2023

It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday!

Via InvestorPlace

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

July 13, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Announces Proposed Public Offering of Common Stock

July 13, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

July 13, 2023

From Caribou Biosciences, Inc.

Via GlobeNewswire

3 Biotech Stocks to Buy for Long-Term Gains

July 13, 2023

The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.

Via MarketBeat

Topics ETFs Economy

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 07, 2023

Via Benzinga

Pfizer Just Invested $25 million In This Biotech

July 07, 2023

Pfizer's investment propels Caribou Biosciences' stock and fuels optimism for its lead candidates: CB-010 and CB-011, both currently in phase 1 trials.

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.